Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1144220210270030141
Journal of Menopausal Medicine
2021 Volume.27 No. 3 p.141 ~ p.145
Hormonal Replacement Therapy and Risk of Thyroid Cancer in Women: A Meta-Epidemiological Analysis of Prospective Cohort Studies
Bae Jong-Myon

Abstract
Objectives: Many experimental studies have reported that female sex hormones involve thyroid cancer development because the incidence rate of thyroid cancer in women (TCW) is 3 times higher than in men. Three previous systematic reviews reporting no association between hormone replacement therapy (HRT) and TCW risk had the same search year of 2014. The aim was to reevaluate the association between HRT use and TCW risk using a meta-epidemiological study of prospective cohort studies.

Methods: The study preferentially used all studies selected by the existing systematic reviews and then secured an additional cohort from the list citing the studies. The selection criterion was defined as the prospective cohort study assessing the association between HRT and TCW risk by adjusted relative risk and its 95% confidence intervals (CI) from multivariate analysis. A random-effects model meta-analysis was applied to estimate summary relative risk (sRR) and its 95% CI. A publication bias was evaluated by Egger¡¯s test; moreover, the statistical significance level was set at 5%.

Results: Nine cohort studies were finally selected. The random-effect model was applied because of heterogeneity (I2 = 64.3%). The sRR and its 95% CI from a random-effects model meta-analysis had no statistical significance in the association between HRT and TCW risk (sRR = 1.11; 95% CI, 0.98?1.26). Additionally, Egger¡¯s test revealed no statistical significance (P = 0.91).

Conclusions: HRT is not associated with TCW risk based on the random-effects model meta-analysis of prospective cohort studies published until now.
KEYWORD
Hormone replacement therapy, Meta-analysis, Risk factor, Thyroid neoplasms
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI)